PMID- 31760494
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20221017
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 21
IP  - 11
DP  - 2019 Nov 23
TI  - Evidence for and Against ACC/AHA 2017 Guideline for Target Systolic Blood 
      Pressure of < 130 mmHg in Persons with Type 2 Diabetes.
PG  - 149
LID - 10.1007/s11886-019-1251-4 [doi]
AB  - PURPOSE OF REVIEW: We summarize the evidence for and against a target systolic 
      blood pressure (SBP) < 130 mmHg in individuals with type 2 diabetes mellitus 
      (T2DM). RECENT FINDINGS: The primary ACCORD trial pooled data from patients with 
      more- and less-intense glycemic control and found no benefit to lowering SBP 
      < 140 mmHg, findings consistent with multiple meta-analyses. However, a 
      re-analysis of the ACCORD trial found that participants randomized to 
      less-intense glycemic control (HbA1c 7.0-7.9%) benefited from targeting SBP < 120 
      vs. 140 mmHg. The SPRINT trial also found benefit for targeting SBP < 120 vs. 
      140 mmHg in participants at risk for cardiovascular events but excluded persons 
      with T2DM. There is no consensus as to the optimal SBP target for patients with 
      T2DM, though data suggest a benefit to targeting SBP < 130 mmHg in patients with 
      less-intensive glucose control. Further research is also needed on BP control in 
      the setting of newer anti-diabetic agents.
FAU - Shen, Jenny I
AU  - Shen JI
AD  - Division of Nephrology and Hypertension, Los Angeles Biomedical Research 
      Institute at Harbor-UCLA Medical Center, 1000 W. Carson St., Box 406, Torrance, 
      CA, 90509, USA. jshen@labiomed.org.
AD  - Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 
      USA. jshen@labiomed.org.
FAU - Nicholas, Susanne B
AU  - Nicholas SB
AD  - Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 
      USA.
AD  - Division of General Internal Medicine and Health Services Research, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA, USA.
FAU - Williams, Sandra
AU  - Williams S
AD  - Providence St. Joseph Health, Los Angeles, CA, USA.
FAU - Norris, Keith C
AU  - Norris KC
AD  - Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 
      USA.
AD  - Division of General Internal Medicine and Health Services Research, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA, USA.
LA  - eng
GR  - K23 DK103972/DK/NIDDK NIH HHS/United States
GR  - P30 AG021684/AG/NIA NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20191123
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - *Antihypertensive Agents/therapeutic use
MH  - Blood Pressure
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Humans
MH  - *Hypertension/complications/drug therapy
MH  - *Hypoglycemic Agents/therapeutic use
MH  - Risk Factors
PMC - PMC6984818
MID - NIHMS1067004
OTO - NOTNLM
OT  - Blood pressure
OT  - Clinical guidelines
OT  - Diabetes
COIS- Conflict of Interest Jenny I. Shen, Susanne B. Nicholas, Sandra Williams, and 
      Keith C. Norris declare that they have no conflict of interest.
EDAT- 2019/11/25 06:00
MHDA- 2020/05/12 06:00
PMCR- 2020/11/23
CRDT- 2019/11/25 06:00
PHST- 2019/11/25 06:00 [entrez]
PHST- 2019/11/25 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
PHST- 2020/11/23 00:00 [pmc-release]
AID - 10.1007/s11886-019-1251-4 [pii]
AID - 10.1007/s11886-019-1251-4 [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2019 Nov 23;21(11):149. doi: 10.1007/s11886-019-1251-4.